The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-11. Anything still debated is marked as such rather than presented as settled.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== B == Baeyer–Drewsen indigo synthesis (also commonly incorrectly named Baeyer–Drewson indigo synthesis) Baeyer–Villiger oxidation, Baeyer–Villiger rearrangement Bakeland process (Bakelite) Baker–Venkataraman rearrangement, Baker–Venkataraman transformation Baldwin's rules Bally–Scholl synthesis Balz–Schiemann reaction Bamberger rearrangement Bamberger triazine synthesis Bamford–Stevens reaction Barbier reaction Barbier–Wieland degradation Bardhan–Sengupta phenanthrene synthesis Barfoed's test Bargellini reaction Bartoli indole synthesis, Bartoli reaction Barton decarboxylation Barton reaction Barton–Kellogg reaction Barton–McCombie reaction, Barton deoxygenation Barton-Zard Synthesis Barton vinyl iodine procedure Baudisch reaction Bayer test Baylis–Hillman reaction Bechamp reaction Bechamp reduction Beckmann fragmentation Beckmann rearrangement Bellus–Claisen rearrangement Belousov–Zhabotinsky reaction Benary reaction Benedict's reagent Benkeser reaction Benzidine rearrangement Benzilic acid rearrangement Benzoin condensation Bergman cyclization Bergmann azlactone peptide synthesis Bergmann degradation Bergmann–Zervas carbobenzoxy method Bernthsen acridine synthesis Bestmann's reagent Betti reaction Biginelli pyrimidine synthesis Biginelli reaction Bingel reaction Birch reduction Bischler–Möhlau indole synthesis Bischler–Napieralski reaction Biuret test Blaise ketone synthesis Blaise reaction Blanc reaction Blanc chloromethylation Blum–Ittah aziridine synthesis Bodroux reaction Bodroux–Chichibabin aldehyde synthesis Bogert–Cook synthesis Bohlmann-Rahtz pyridine synthesis Bohn–Schmidt reaction Boord olefin synthesis Borodin reaction Borsche–Drechsel cyclization Bosch–Meiser urea process Bosch reaction Bouveault aldehyde synthesis Bouveault–Blanc reduction Boyland–Sims oxidation Boyer Reaction Bredt's rule Brook rearrangement Brown hydroboration Bucherer carbazole synthesis Bucherer reaction Bucherer–Bergs reaction Buchner ring enlargement Büchner–Curtius–Schlotterbeck reaction Buchwald–Hartwig amination Bunnett reaction Burgess reagent
There are special risks to consider for older adults, and women who are pregnant. When a person ages, the body becomes less able to rid itself of barbiturates. As a result, people over the age of 65 are at higher risk of experiencing the harmful effects of barbiturates, including drug dependence and accidental overdose. When barbiturates are taken during pregnancy, the drug passes through the placenta to the fetus. After the baby is born, it may experience withdrawal symptoms and have trouble breathing. In addition, nursing mothers who take barbiturates may transmit the drug to their babies through breast milk. A rare adverse reaction to barbiturates is Stevens–Johnson syndrome, which primarily affects the mucous membranes.
=== As a drug target === Given its prominent role in both diabetes and CVD, RAGE is a promising therapeutic target. Preclinical and clinical studies are exploring RAGE antagonism to treat these conditions. Blocking RAGE signaling, either through pharmacological inhibitors or soluble decoy receptors like sRAGE, has shown potential in reducing vascular complications in diabetic patients. These strategies may offer new ways to manage the chronic inflammation and oxidative stress that drive both diabetic complications and cardiovascular disease progression RAGE's role in diabetes and cardiovascular disease highlights the importance of its signaling pathway in mediating chronic inflammation and vascular damage. Targeting RAGE could offer a promising approach to mitigating the burden of these diseases, particularly in patients with diabetes, where current therapies may fall short in preventing cardiovascular complications.
Singapore has a generally efficient healthcare system, having achieved high quality of care while also keeping expenditures low. The World Health Organisation ranks Singapore's healthcare system as 6th overall in the world in its World Health Report. Singapore has had the lowest infant mortality rates in the world for the past two decades. In 2019, Singaporeans had the longest life expectancy of any country at 84.8 years. Women can expect to live an average of 87.6 years with 75.8 years in good health. The averages are lower for men. Singapore is ranked 1st on the Global Food Security Index. As of December 2011 and January 2013, 8,800 foreigners and 5,400 Singaporeans were respectively diagnosed with HIV, but there are fewer than 10 annual deaths from HIV per 100,000 people. Adult obesity is below 10%. There is a high level of immunisation. In 2013, the Economist Intelligence Unit ranked Singapore as having the best quality of life in Asia and sixth overall in the world. The government's healthcare system is based upon the "3M" framework. This has three components: Medifund, which provides a safety net for those not able to otherwise afford healthcare; Medisave, a compulsory national medical savings account system covering about 85% of the population; and Medishield, a government-funded health insurance programme. Public hospitals in Singapore have considerable autonomy in their management decisions, and notionally compete for patients, but remain in government ownership. A subsidy scheme exists for those on low income.
In February 2018, The Marshall Project published an investigation reporting that the new label allowed Johnson & Johnson to market Invega Sustenna as a way to keep people out of prison or jail. John Snook, executive director of the Treatment Advocacy Center, described the "stay-out-of-jail" marketing approach as a "depressing commentary" on the state of mental health treatment. Critics noted that the PRIDE study did not compare Invega Sustenna with other long-acting injectable antipsychotics, only with daily oral antipsychotics, and that the reduced rate of incarceration was likely due to improved drug adherence rather than a unique property of paliperidone palmitate. A 2022 review of internal pharmaceutical industry documents, published in the Journal of Correctional Health Care, identified Janssen as one of at least two companies that directly marketed antipsychotics to jails and prisons to increase sales. The review found that marketing strategies included targeted promotions, indirect "educational" advertising, and efforts to influence state formulary advisory boards. Concerns have also been raised about industry influence on the evidence base for long‑acting injectable (LAI) antipsychotics. In a 2024 paper in Accountability in Research, Lisa Cosgrove and colleagues presented a case analysis arguing that systematic reviews comparing LAIs to oral antipsychotics can be "shaped by commercial interests" and that financial conflicts of interest among review authors may "undermine patient‑centered models of recovery and care."
Sources: en.wikipedia.org
== Uses == Synthetic platelets have diverse therapeutic applications, including treating hemostasis in trauma care, clotting disorders, and immune responses in conditions such as thrombosis, inflammation, and cancer. Originally researched to replicate the biochemistry and cell and molecular biology of natural platelets, platelet-mimicking particles are now in preclinical development for multiple therapeutic applications with specialized drug delivery mechanisms. The need for these particles is informed by increasing rates of reported thrombocytopenia cases and clinical bleeding syndrome diagnoses such as von Willebrand disease or Glanzmann thrombasthenia. Early treatment solutions of the mid-late twentieth century were not based upon current findings in nanoparticle drug delivery technologies, thus lacking the ability to overcome primary limitations of natural platelets. With a diverse assortment of platelet-mimicking particle formulations under testing, their use can be widespread to multiple clinical diagnoses and areas—antimicrobial platelets, cancer, hemorrhage and trauma, bleeding disorders, and cholesterol clearance.
A similar stele fragment (ES 1027), 57 centimeters high by 42 centimeters wide by 20 deep, depicting Naram-Sin was found a few miles north-east of Diarbekr, at Pir Hüseyin in a well, though this was not its original context. It is said to have been first found in Miyafarkin, a village about 75 kilometers northeast of Diarbekr. Fragments of an alabaster stele representing captives being led by Akkadian soldiers is sometimes attributed to Narim-Sin (or Rimush or Manishtushu) on stylistic grounds. In particular, it is considered as more sophisticated graphically than the steles of Sargon of Akkad or those of Rimush or Manishtushu. Two fragments (IM 55639 and IM 59205) are in the National Museum of Iraq, and one (MFA 66.89) is the Boston Museum. The stele is quite fragmentary, but attempts at reconstitution have been made. Depending on sources, the fragments were excavated in Wasit, al-Hay district, Wasit Governorate, or in Nasiriyah, both locations in Iraq. It is thought that the stele represents the result of the campaigns of Naram-Sin to Cilicia or Anatolia. This is suggested by the characteristics of the booty carried by the soldiers in the stele, especially the metal vessel carried by the main soldier, the design of which is unknown in Mesopotamia, but on the contrary well known in contemporary Anatolia.
=== Dextran nanoparticle applications === Dextran nanoparticles have advantages such as increased drug-loading capacity, improved cellular uptake, reduce off-site toxicity, and increase local drug concentrations at the target tissue site. The current research indicates that dextran nanoparticles can potentially have applications in the delivery of anti-tumor therapeutics.
On 21 March, Japanese ambassador to Brazil Teiji Hayashi confirmed that prime minister Fumio Kishida would invite president Lula to the 49th G7 summit to be held from 19 to 21 May 2023 in Hiroshima, which formally took place on 6 April. In May 2023, Kishida met with Lula and announced that Japan was starting procedures to grant Brazilians travel visa exemptions and was opening a ¥30 billion line of credit to support health companies and other businesses in Brazil through Japan International Cooperation Agency (JICA). Lula said Brazil and Japan need to further develop their commercial, cultural, political and scientific relationship adding that "we have cultural bonds with Japan and a great Japanese-Brazilian community". Both leaders also discussed education, climate change, development and peace.
=== Batten disease === Milasen is a novel individualized therapeutic agent that was designed and approved by the FDA for the treatment of Batten disease. This therapy serves as an example of personalized medicine. In 2019, a report was published detailing the development of milasen, an antisense oligonucleotide drug for Batten disease, under an expanded-access investigational clinical protocol authorized by the Food and Drug Administration (FDA). Milasen "itself remains an investigational drug, and it is not suited for the treatment of other patients with Batten's disease" because it was customized for a single patient's specific mutation. However it is an example of individualized genomic medicine therapeutical intervention.
Sources: en.wikipedia.org
==== Distribution ==== The brain tissue distribution of muscimol in rats has been studied. Muscimol rapidly enters and unevenly distributes in rat brain, especially in the substantia nigra, colliculi, and hypothalamus. Muscimol crosses the blood–brain barrier and hence is centrally active. This has been said to likely be mediated by active transport via the high-affinity GABA uptake system and other amino acid transporters. Although muscimol crosses the blood–brain barrier, it does so relatively poorly and far less readily than gaboxadol.
=== 11 April === Denmark's Acting Defence Minister, Troels Lund Poulsen, stated that Denmark will provide Ukraine with Leopard 1A5 tanks before summer, and hopes to provide as many as 100 within six months. The Russian State Duma passed legislation to change the nature of conscription summons and how they were served. Previously a summons had to be physically served on the person being called up. Now a summons is deemed to be served once it appears on the government services portal called "Gosuslugi". Failure to obey such a summons could mean potential "bans on driving, registering a company, working as a self-employed individual, obtaining credit or loans, selling apartments, buying property or securing social benefits."
Loss of E-cadherin is considered to be a fundamental event in EMT. Many transcription factors (TFs) that can repress E-cadherin directly or indirectly can be considered as EMT-TF (EMT inducing TFs). SNAI1/Snail 1, SNAI2/Snail 2 (also known as Slug), ZEB1, ZEB2, TCF3 and KLF8 (Kruppel-like factor 8) can bind to the E-cadherin promoter and repress its transcription, whereas factors such as Twist, Goosecoid, TCF4 (also known as E2.2), homeobox protein SIX1 and FOXC2 (fork-head box protein C2) repress E-cadherin indirectly. SNAIL and ZEB factors bind to E-box consensus sequences on the promoter region, while KLF8 binds to promoter through GT boxes. These EMT-TFs not only directly repress E-cadherin, but also repress transcriptionally other junctional proteins, including claudins and desmosomes, thus facilitating EMT. On the other hand, transcription factors such as grainyhead-like protein 2 homologue (GRHL2), and ETS-related transcription factors ELF3 and ELF5 are downregulated during EMT and are found to actively drive MET when overexpressed in mesenchymal cells. Since EMT in cancer progression recaptures EMT in developmental programs, many of the EMT-TFs are involved in promoting metastatic events. Several signaling pathways (TGF-β, FGF, EGF, HGF, Wnt/beta-catenin and Notch) and hypoxia may induce EMT. In particular, Ras-MAPK has been shown to activate Snail and Slug. Slug triggers the steps of desmosomal disruption, cell spreading, and partial separation at cell–cell borders, which comprise the first and necessary phase of the EMT process.
=== Burnt sugars and caramels === Heating sugar to near 200 °C for several minutes yields a product called burnt sugar. Often additives are used to modify the resulting caramels, e.g. alkali or sulfites. Several volatile products evolve in the heating process including butanone, several furans (2-Acetylfuran, furanone, hydroxymethyl furfural), and levoglucosan and more. Because sugars burn easily when exposed to flame, the handling of sugar powders risks dust explosion. The 2008 Georgia Imperial sugar refinery explosion, which killed 14 people and injured 36, and destroyed most of the refinery, was caused by the ignition of sugar dust.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.